Shots:

• Cerevance to receive upfront technology access fee- pre/-clinical- development- commercialization milestones of up to $170M/ target and royalties on global sales of products. Takeda will support the research to identify novel target proteins expressed in the CNS and to develop new therapies targeting GI disorders
• The multi-year collaboration will leverage Cerevance’s NETSseq technology to identify new therapies targeting the unmet medical needs of patients with GI disease
• Cerevance’s NETSseq target discovery platform utilizes Ab nuclear proteins- ER proteins and membrane proteins along with RNA probes against any cell-type-specific transcripts and enables the measurement of genes

Click here to­ read full press release/ article | Ref: Cerevance | Image: Cerevance